Inventia Life Science: Raises $25M in Series B Funding

Inventia Life Science Raises $25M in Series B Funding

  • Inventia Life Science, a Sidney, Australia-based world leader in advanced 3D cell cultures for research and clinical purposes, closed a US $25M Series B funding round
  • The round was led by Blackbird Ventures with participation from Skip Capital
  • Inventia has also announced the launch of its US operations with the appointment of Dwayne Dexter as its Director of US Sales
  • Dr. Dexter will be instrumental in growing the pharmaceutical and academic customer base and driving adoption of Inventia’s technology in the US and Canada
  • Founded by CEO Dr. Julio Ribeiro Dr. Aidan O’Mahony, Dr. Cameron Ferris and Peter Arthur in 2013, Inventia is creating tools for advanced biomedical discovery
  • The company is headquartered in Sydney, Australia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

NYSE Parent Invests $600M in Polymarket, Strengthening Market Position

This significant investment signals confidence in the future of predictive markets.Highlights: NYSE's parent company allocates $600M to Polymarket.Investment...

Nexi Expands SEPA Direct Debit with Danish Banks, Enhancing Payments Integration

Nexi's collaboration with Danish banks aims to strengthen payment services across Europe.Highlights: Nexi partners with several Danish banks...

Lloyds Confirms App Glitch Exposed Data of Almost Half a Million Customers

The significant data breach prompts concerns over customer privacy.Highlights: Lloyds Banking Group admits to a data breach affecting...

Mastercard Restricts Sale of Nets Payments Unit Purchased for $3.2 Billion

Mastercard looks to divest its Nets payments segment as part of strategic realignment.Highlights: Mastercard is seeking to sell...